12:00 AM
Jan 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Sphingomab: Phase IIa halted

Lpath suspended dosing in the Phase Ib PEDigree and Phase IIa Nexus trials because its fill/finish contractor, Formatech Inc. (Andover, Mass.), did not meet cGMP requirements. Lpath said the move is precautionary and it has received no reports of safety concerns associated with iSONEP. The company identified an alternative fill/finish contractor and plans to resume dosing in both trials within 4-6 months. Pfizer Inc. (NYSE:PFE, New York, N.Y.)...

Read the full 329 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >